Search CPIX
CUMBERLAND PHARMACEUTICALS INC
Nasdaq · CIK 1087294
Last close7.39
Daily change-0.12 (-1.60%)
10 Years gain+77.45%
Dividends TTM1.5
Dividend yield19.97%
Fundamental Analysis
CPIX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
25.4Momentum
0.0Acceleration
0.0Confidence
83.0Annual Revenue17
Quarterly Revenue76
Annual CFO17
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth2.6 / 25
Quality4.4 / 25
Capital Efficiency5.0 / 20
Balance Sheet6.4 / 15
Shareholder Economics5.7 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Operating margin compression · MEDIUMOperating margin compressed by 11.374 percentage points.
ROIC declining · MEDIUMROIC declined by 15.5931 percentage points.
Key Metrics
Revenue Growth TTM-5.15%OK
Revenue CAGR 3Y1.95%OK
Gross Marginn/aMISSING
Operating Margin-24.12%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-59.7%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.14%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $44.52M | $37.85M | -$2.79M | $4.93M | $4.83M | 85.02% | -6.27% | 10.86% | -18.83% | 14.85M |
| 2025 FY Dec 31, 2024 | $37.87M | $31.28M | -$6.43M | -$612,186.00 | -$678,647.00 | 82.61% | -16.99% | -1.79% | -47.78% | 14.06M |
| 2024 FY Dec 31, 2023 | $39.55M | $33.49M | -$9.55M | $6.09M | $5.81M | 84.66% | -24.16% | 14.7% | -54.32% | 14.3M |
| 2023 FY Dec 31, 2022 | $42.01M | $32.89M | -$5.70M | $8.45M | $8.35M | 78.29% | -13.58% | 19.88% | -27.92% | 14.56M |
| 2022 FY Dec 31, 2021 | $35.05M | $26.23M | -$7.68M | $6.34M | $6.24M | 74.86% | -21.91% | 17.8% | -31.91% | 14.9M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $39.90M | sum latest 4 fiscal quarters Revenue | OK | 0001087294-26-000020, 0001087294-26-000049 |
| Revenue Growth TTM | -5.15% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001087294-26-000020, 0001087294-26-000049 |
| Revenue CAGR 3Y | 1.95% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001087294-26-000020 |
| Revenue CAGR 5Y | 4.43% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001087294-26-000020 |
| Gross Profit CAGR 3Y | 4.79% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001087294-26-000020 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001087294-26-000020, 0001087294-26-000049 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | -24.12% | Operating Income / Revenue | OK | 0001087294-26-000020, 0001087294-26-000049 |
| ROIC | -59.7% | NOPAT / Average Invested Capital | OK | 0001087294-26-000020, 0001087294-26-000049 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001087294-26-000062 |
| Current Ratio | 0.96x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $2.66 | Revenue / Diluted Shares | OK | 0001087294-26-000020, 0001087294-26-000049 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001087294-26-000020 |